Accessibility Menu
Veradermics logo

Veradermics

(NYSE) MANE

Current Price$111.64
Market Cap$4.42BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2026)+180%
5 YearN/A
1 YearN/A
1 Month+16%
Veradermics last closing stock price
MetricPriceDate
Last closeUSD 105.832026-07-16
Veradermics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-15.27%USD 124.912026-07-09
1 month+16.36%USD 90.952026-06-16
3 month+38.72%USD 76.292026-04-17
Since inception+180.34%USD 37.752026-02-04

Veradermics Financials at a Glance

Market Cap

$4.42BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$67.14

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-0.42 (Low)

Price

$111.64

Volume

949,924

Open

$108.51

Previous Close

$111.32

Daily Range

$105.01 - $117.82

52-Week Range

$17.00 - $131.24

Estimated Earnings Date

Aug 11, 2026

MANE News

BuyAlert-Purple.png

This Fund Has a $75 Million Bet on a Hair Loss Biotech Stock Up More Than 500% Post-IPO

Jonathan PoncianoMay 14, 2026

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Veradermics

Veradermics helps people treat hair loss and skin issues. These products solve problems for adults and children with common dermatology needs. The company makes taking medicine easier and more effective.

Treatments for Hair and Skin

  • VDPHL01: Oral, extended-release pill for men and women with chronic hair loss; designed to increase follicular saturation without affecting heart activity.
  • VDMN: Dissolvable patch for treating common warts; uses microarray technology to deliver immunotherapy directly through the skin.
  • VDAA: Clinical-stage therapeutic for alopecia areata; targets an autoimmune condition that causes patches of hair loss on the scalp and body.
  • VDMC: Specialized treatment for molluscum contagiosum; addresses a viral infection that produces small bumps on the skin of children and adults.

Funding the Pipeline

  • Completed its initial public offering in February 2026, generating $269.1 million in net proceeds for clinical development.
  • Announced positive results from its Phase 2/3 Study '302' in April 2026, showing significant hair growth in male patients.
  • Raised $442 million in May 2026 through a follow-on public offering to support commercial launch preparations.
  • Sold pre-funded warrants to Suvretta Capital in May 2026, securing $30 million in additional private funding.

Changing How Medicine Is Delivered

Veradermics focuses on extended-release technology to maximize the impact of hair restoration while minimizing side effects. By targeting the cash-pay healthcare market, the company aims to bypass traditional insurance hurdles and sell directly to patients.

By the Numbers

  • Operating expenses reached $29.9 million in Q1 2026, up from $12.9 million in Q1 2025.
  • Research and development costs rose to $20.9 million in Q1 2026, an increase from $11.4 million in Q1 2025.
  • Net loss deepened to $27.2 million for the quarter ending March 31, 2026, compared to $12.4 million in the prior year.
  • Cash and cash equivalents grew to $168.4 million by March 31, 2026, following the initial public offering.
  • Operating cash flow worsened to -$21.2 million in Q1 2026, down from -$13.3 million in Q1 2025.

Bottom Line

Veradermics has transitioned from a private startup to a well-funded public company focused on the dermatology market. Its focus on specialized skin and hair treatments positions it as a late-stage developer in the aesthetics sector.

AI Generated • May 22, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

24

CEO

Reid Waldman, MD

Website

www.veradermics.com

Headquarters

New Haven, CT 06513, US

MANE Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-84.21%

Return on Capital

N/A

Return on Assets

-12.31%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$4.42BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

41.78M

Volume

949.92K

Avg. Volume

684.64K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$58.84M

EBITDA

-$53.92M

Operating Cash Flow

-$48.43M

Capital Expenditure

-$5.00K

Free Cash Flow

-$48.43M

Cash & ST Invst.

$390.80M

Total Debt

$0.00

Veradermics Performance Analysis

Veradermics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Veradermics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Veradermics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-12-31USD -0.47N/A
20242024-12-31USD -0.7865.6%
20252025-12-31USD -2.23186.8%
Veradermics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31-5.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$4.42BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$210.54M

N/A

Employees

21

N/A

Net Income

-$27.23M

N/A

EBITDA

-$27.23M

N/A

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$390.80M

N/A

Total Debt

$0.00

N/A

Accounts Receivable

$1.65M

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-12.31%

N/A

Return on Invested Capital

-13.49%

N/A

Free Cash Flow

-$21.17M

N/A

Operating Cash Flow

-$21.17M

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
TVTXTravere Therapeutics, Inc.
$56.71+2.59%
ABEOAbeona Therapeutics Inc.
$7.00-0.28%
HELPCybin Inc. Common Stock
$7.25+2.98%
OVIDOvid Therapeutics Inc.
$2.44-0.41%

Trending Stocks

Symbol / CompanyPricePrice Chg
ONDSOndas
$6.53-0.02%
AALAmerican Airlines Group
$14.98-0.04%
INTCIntel
$95.04-0.02%
NOKNokia
$10.12-0.03%

Questions About MANE

What is the current price of Veradermics?

Veradermics is trading at $111.32 per share.

What is the 52-week range for Veradermics?

Over the past 52 weeks, Veradermics has traded between $17.00 and $131.24.

How much debt does Veradermics have?

As of the most recent reporting period, Veradermics reported total debt of $0.00.

How much cash does Veradermics have on hand?

Veradermics reported $168.41M in cash and cash equivalents in its most recent financial results.

What is Veradermics’s dividend yield?

Veradermics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services